Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

HitGen Forms Drug Discovery Partnership with Gilead Sciences

publication date: Jun 3, 2019

Chengdu's HitGen announced a drug discovery collaboration with Gilead Sciences to identify small molecule leads against targets specified by Gilead. HitGen will use its technology platform, based on DNA-encoded library design, synthesis and interrogation, to discover novel leads. HitGen believes its DNA encoded chemical libraries (DELs) contain 400 billion highly diverse, drug-like small molecules and macrocycles. HitGen will receive an undisclosed upfront payment and will be eligible for milestone payments from Gilead. More details....

Stock Symbol: (NSDQ: GILD)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.